AAP News Vol. 14 No. 5 May 1998, p. 3
© 1998 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dell'Aringa, S.
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Treating allergic rhinitis

Stefanie Dell'Aringa

Intranasal corticosteriods effectively control most symptoms of allergic rhinitis (AR) with minimal side effects and can be "a wise choice" for many pediatric patients, according to a California review.

AR is common, affecting one in five children by age 3 years, approximately 40 percent of children by age 6 years and approximately 30 percent of adolescents.

Due to its physical manifestations, AR can affect self-esteem and interfere with learning, concentration and psychosocial behavior. Besides its discomfort, untreated AR can predispose patients to more serious respiratory diseases.